{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:46:48Z","timestamp":1790614008173,"version":"4.1.0"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The association of adjuvant chemotherapy (AC) with survival in the general population of patients with resected biliary tract cancer (BTC) remains controversial. As such, the role of this treatment in the treatment of older adult patients (aged \u226570 years) needs to be evaluated.<\/jats:p><\/jats:sec>Objective<\/jats:title>To describe the patterns of use of AC and compare survival outcomes of AC and observation in older adult patients following resection of BTC.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study included 8091 older adult patients with resected BTC with data available in the National Cancer Database from January 1, 2004, to December 31, 2019. Patients were divided into 2 cohorts: AC and observation. The AC cohort was subdivided into single-agent and multiagent AC treatment.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Adjuvant chemotherapy vs observation following BTC resection.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was overall survival (OS) of patients who received AC compared with observation following resection of BTC as evaluated using Kaplan-Meier estimates and multivariable Cox proportional hazards regression models. Inverse probability of treatment weighting and propensity score matching were performed to address indication bias.<\/jats:p><\/jats:sec>Results<\/jats:title>Between 2004 and 2019, of 8091 older adult patients with resected BTC identified (median [range] age, 77 [70-90] years; 5136 women [63.5%]; 2955 men [36.5%]), only one-third (2632 [32.5%]) received AC. There was an increase in the use of AC across the study period from 20.7% (n\u2009=\u2009495) in 2004 to 2009 to 41.2% (n\u2009=\u2009856) in 2016 to 2019. Age 80 years or older (odds ratio, 0.29; 95% CI, 0.25-0.33; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and gallbladder primary site (odds ratio, 0.71; 95% CI, 0.61-0.83; P<\/jats:italic>\u2009&amp;lt;\u2009.001) were associated with a lower odds of AC. Following inverse probability of treatment weighting, as a composite, AC was not associated with improved survival (median OS, 20.5 months; 95% CI, 19.2-21.7 months) compared with observation (median OS, 19.0 months; 95% CI, 18.1-20.3 months). A longer median OS was associated with single-agent AC (21.5 months; 95% CI, 19.9-24.0 months) but not multiagent AC (19.1 months; 95% CI, 17.5-21.1 months) compared with observation (median OS, 17.3 months; 95% CI, 16.1-18.4 months). This improvement in OS with single-agent AC was not apparent on multivariable analysis (hazard ratio [HR], 0.97; 95% CI, 0.89-1.05; P<\/jats:italic>\u2009=\u2009.44). However, age at diagnosis of 80 years or older (HR, 1.35; 95% CI, 1.28-1.42; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and treatment at nonacademic centers (HR, 1.14; 95% CI, 1.07-1.20, P<\/jats:italic>\u2009&amp;lt;\u2009.001) were associated with worse OS.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of older adult patients, AC was not associated with an improvement in survival compared with observation following BTC resection. These findings suggest the need for further study of AC for older adult patients who may benefit after curative intent surgery for BTC.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.51502","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T16:00:50Z","timestamp":1704988850000},"page":"e2351502","source":"Crossref","is-referenced-by-count":9,"title":["Adjuvant Chemotherapy and Outcomes in Older Adult Patients With Biliary Tract Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Olumide B.","family":"Gbolahan","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Zhi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir M.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Kooby","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatunji B.","family":"Alese","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"zoi231505r1","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.2147\/CMAR","article-title":"Biliary tract cancers: current knowledge, clinical candidates and future challenges.","volume":"11","author":"Tariq","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"1","key":"zoi231505r2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/s12876-022-02637-8","article-title":"The epidemiological trends of biliary tract cancers in the United States of America.","volume":"22","author":"Jiang","year":"2022","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"zoi231505r3","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise.","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"issue":"4","key":"zoi231505r4","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.surg.2017.08.011","article-title":"Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach.","volume":"163","author":"Komaya","year":"2018","journal-title":"Surgery"},{"issue":"3","key":"zoi231505r5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"issue":"8","key":"zoi231505r6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study.","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi231505r7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"zoi231505r8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5114\/ceh.2019.85166","article-title":"Epidemiology of gallbladder cancer.","volume":"5","author":"Rawla","year":"2019","journal-title":"Clin Exp Hepatol"},{"issue":"1","key":"zoi231505r9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/epirev\/mxs009","article-title":"Multimorbidity in older adults.","volume":"35","author":"Salive","year":"2013","journal-title":"Epidemiol Rev"},{"issue":"6","key":"zoi231505r10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/annonc\/mdu540","article-title":"The prevalence and outcomes of frailty in older cancer patients: a systematic review.","volume":"26","author":"Handforth","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"zoi231505r11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3816\/CCC.2005.n.040","article-title":"Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.","volume":"5","author":"Ho","year":"2005","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"zoi231505r12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.clcc.2014.06.002","article-title":"Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience.","volume":"13","author":"Kim","year":"2014","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"zoi231505r13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pan.2019.11.012","article-title":"The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer.","volume":"20","author":"Li","year":"2020","journal-title":"Pancreatology"},{"issue":"10372","key":"zoi231505r14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.","volume":"401","author":"Nakachi","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"zoi231505r15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.dld.2022.08.036","article-title":"Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial.","volume":"55","author":"Aparicio","year":"2023","journal-title":"Dig Liver Dis"},{"issue":"2","key":"zoi231505r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.46912","article-title":"A propensity score analysis of chemotherapy use in patients with resectable gallbladder cancer.","volume":"5","author":"Ozer","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi231505r17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw202","article-title":"Adjuvant therapy for resected gallbladder cancer: analysis of the national cancer data base.","volume":"109","author":"Mantripragada","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"zoi231505r18","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.21037\/jgo","article-title":"Adjuvant treatment for the elderly patient with resected gallbladder cancer: a SEER-Medicare analysis.","volume":"13","author":"de Savornin Lohman","year":"2022","journal-title":"J Gastrointest Oncol"},{"issue":"13","key":"zoi231505r19","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1245\/s10434-017-6095-9","article-title":"Identification of patients for adjuvant therapy after resection of carcinoma of the extrahepatic bile ducts: a propensity score-matched analysis.","volume":"24","author":"Ecker","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"27","key":"zoi231505r20","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.2012.42.5645","article-title":"Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.","volume":"30","author":"Tournigand","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi231505r21","doi-asserted-by":"publisher","first-page":"e631","DOI":"10.1200\/JOP.18.00175","article-title":"Comorbidity assessment in the national cancer database for patients with surgically resected breast, colorectal, or lung cancer (AFT-01, -02, -03).","volume":"14","author":"Wong","year":"2018","journal-title":"J Oncol Pract"},{"issue":"5","key":"zoi231505r22","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1097\/HEP.0000000000000046","article-title":"Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.","volume":"77","author":"Jeong","year":"2023","journal-title":"Hepatology"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2813838\/gbolahan_2024_oi_231505_1704315991.55162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T16:00:54Z","timestamp":1704988854000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2813838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.51502","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]}}}